Function of integrin-linked kinase in modulating the stemness of il-6-abundant breast cancer cells by regulating γ-secretase-mediated notch1 activation in caveolae

En Chi Hsu, Samuel K. Kulp, Han Li Huang, Huang Ju Tu, Santosh B. Salunke, Nicholas J. Sullivan, Duxin Sun, Max S. Wicha, Charles L. Shapiro, Ching Shih Chen

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Interleukin-6 (IL-6) and Notch signaling are important regulators of breast cancer stem cells (CSCs), which drive the malignant phenotype through self-renewal, differentiation, and development of therapeutic resistance. We investigated the role of integrin-linked kinase (ILK) in regulating IL-6-driven Notch1 activation and the ability to target breast CSCs through ILK inhibition. Ectopic expression/short hairpin RNA-mediated knockdown of ILK, pharmacological inhibition of ILK with the small molecule T315, Western blot analysis, immunofluorescence, and luciferase reporter assays were used to evaluate the regulation of IL-6-driven Notch1 activation by ILK in IL-6-producing triple-negative breast cancer cell lines (MDA-MB-231, SUM-159) and in MCF-7 and MCF-7IL-6 cells. The effects of ILK on γ-secretase complex assembly and cellular localization were determined by immunofluorescence, Western blots of membrane fractions, and immunoprecipitation. In vivo effects of T315-induced ILK inhibition on CSCs in SUM-159 xenograft models were assessed by mammosphere assays, flow cytometry, and tumorigenicity assays. Results show that the genetic knockdown or pharmacological inhibition of ILK suppressed Notch1 activation and the abundance of the γ-secretase components presenilin-1, nicastrin, and presenilin enhancer 2 at the posttranscriptional level via inhibition of caveolin-1-dependent membrane assembly of the γ-secretase complex. Accordingly, knockdown of ILK inhibited breast CSC-like properties in vitro and the breast CSC subpopulation in vivo in xenograft tumor models. Based on these findings, we propose a novel function of ILK in regulating γ-secretase-mediated Notch1 activation, which suggests the targeting of ILK as a therapeutic approach to suppress IL-6-induced breast CSCs.

Original languageEnglish
Pages (from-to)497-508
Number of pages12
JournalNeoplasia
Volume17
Issue number6
DOIs
Publication statusPublished - Jan 1 2015
Externally publishedYes

Fingerprint

Caveolae
Amyloid Precursor Protein Secretases
Breast Neoplasms
Neoplastic Stem Cells
Interleukin-6
Heterografts
Fluorescent Antibody Technique
integrin-linked kinase
Presenilin-2
Western Blotting
Pharmacology
Triple Negative Breast Neoplasms
Presenilin-1
Caveolin 1
Membranes
Luciferases
Immunoprecipitation
Small Interfering RNA
Flow Cytometry

ASJC Scopus subject areas

  • Cancer Research
  • Medicine(all)

Cite this

Function of integrin-linked kinase in modulating the stemness of il-6-abundant breast cancer cells by regulating γ-secretase-mediated notch1 activation in caveolae. / Hsu, En Chi; Kulp, Samuel K.; Huang, Han Li; Tu, Huang Ju; Salunke, Santosh B.; Sullivan, Nicholas J.; Sun, Duxin; Wicha, Max S.; Shapiro, Charles L.; Chen, Ching Shih.

In: Neoplasia, Vol. 17, No. 6, 01.01.2015, p. 497-508.

Research output: Contribution to journalArticle

Hsu, En Chi ; Kulp, Samuel K. ; Huang, Han Li ; Tu, Huang Ju ; Salunke, Santosh B. ; Sullivan, Nicholas J. ; Sun, Duxin ; Wicha, Max S. ; Shapiro, Charles L. ; Chen, Ching Shih. / Function of integrin-linked kinase in modulating the stemness of il-6-abundant breast cancer cells by regulating γ-secretase-mediated notch1 activation in caveolae. In: Neoplasia. 2015 ; Vol. 17, No. 6. pp. 497-508.
@article{418c75793b664e758cdf58519dd8ea58,
title = "Function of integrin-linked kinase in modulating the stemness of il-6-abundant breast cancer cells by regulating γ-secretase-mediated notch1 activation in caveolae",
abstract = "Interleukin-6 (IL-6) and Notch signaling are important regulators of breast cancer stem cells (CSCs), which drive the malignant phenotype through self-renewal, differentiation, and development of therapeutic resistance. We investigated the role of integrin-linked kinase (ILK) in regulating IL-6-driven Notch1 activation and the ability to target breast CSCs through ILK inhibition. Ectopic expression/short hairpin RNA-mediated knockdown of ILK, pharmacological inhibition of ILK with the small molecule T315, Western blot analysis, immunofluorescence, and luciferase reporter assays were used to evaluate the regulation of IL-6-driven Notch1 activation by ILK in IL-6-producing triple-negative breast cancer cell lines (MDA-MB-231, SUM-159) and in MCF-7 and MCF-7IL-6 cells. The effects of ILK on γ-secretase complex assembly and cellular localization were determined by immunofluorescence, Western blots of membrane fractions, and immunoprecipitation. In vivo effects of T315-induced ILK inhibition on CSCs in SUM-159 xenograft models were assessed by mammosphere assays, flow cytometry, and tumorigenicity assays. Results show that the genetic knockdown or pharmacological inhibition of ILK suppressed Notch1 activation and the abundance of the γ-secretase components presenilin-1, nicastrin, and presenilin enhancer 2 at the posttranscriptional level via inhibition of caveolin-1-dependent membrane assembly of the γ-secretase complex. Accordingly, knockdown of ILK inhibited breast CSC-like properties in vitro and the breast CSC subpopulation in vivo in xenograft tumor models. Based on these findings, we propose a novel function of ILK in regulating γ-secretase-mediated Notch1 activation, which suggests the targeting of ILK as a therapeutic approach to suppress IL-6-induced breast CSCs.",
author = "Hsu, {En Chi} and Kulp, {Samuel K.} and Huang, {Han Li} and Tu, {Huang Ju} and Salunke, {Santosh B.} and Sullivan, {Nicholas J.} and Duxin Sun and Wicha, {Max S.} and Shapiro, {Charles L.} and Chen, {Ching Shih}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.neo.2015.06.001",
language = "English",
volume = "17",
pages = "497--508",
journal = "Neoplasia",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Function of integrin-linked kinase in modulating the stemness of il-6-abundant breast cancer cells by regulating γ-secretase-mediated notch1 activation in caveolae

AU - Hsu, En Chi

AU - Kulp, Samuel K.

AU - Huang, Han Li

AU - Tu, Huang Ju

AU - Salunke, Santosh B.

AU - Sullivan, Nicholas J.

AU - Sun, Duxin

AU - Wicha, Max S.

AU - Shapiro, Charles L.

AU - Chen, Ching Shih

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Interleukin-6 (IL-6) and Notch signaling are important regulators of breast cancer stem cells (CSCs), which drive the malignant phenotype through self-renewal, differentiation, and development of therapeutic resistance. We investigated the role of integrin-linked kinase (ILK) in regulating IL-6-driven Notch1 activation and the ability to target breast CSCs through ILK inhibition. Ectopic expression/short hairpin RNA-mediated knockdown of ILK, pharmacological inhibition of ILK with the small molecule T315, Western blot analysis, immunofluorescence, and luciferase reporter assays were used to evaluate the regulation of IL-6-driven Notch1 activation by ILK in IL-6-producing triple-negative breast cancer cell lines (MDA-MB-231, SUM-159) and in MCF-7 and MCF-7IL-6 cells. The effects of ILK on γ-secretase complex assembly and cellular localization were determined by immunofluorescence, Western blots of membrane fractions, and immunoprecipitation. In vivo effects of T315-induced ILK inhibition on CSCs in SUM-159 xenograft models were assessed by mammosphere assays, flow cytometry, and tumorigenicity assays. Results show that the genetic knockdown or pharmacological inhibition of ILK suppressed Notch1 activation and the abundance of the γ-secretase components presenilin-1, nicastrin, and presenilin enhancer 2 at the posttranscriptional level via inhibition of caveolin-1-dependent membrane assembly of the γ-secretase complex. Accordingly, knockdown of ILK inhibited breast CSC-like properties in vitro and the breast CSC subpopulation in vivo in xenograft tumor models. Based on these findings, we propose a novel function of ILK in regulating γ-secretase-mediated Notch1 activation, which suggests the targeting of ILK as a therapeutic approach to suppress IL-6-induced breast CSCs.

AB - Interleukin-6 (IL-6) and Notch signaling are important regulators of breast cancer stem cells (CSCs), which drive the malignant phenotype through self-renewal, differentiation, and development of therapeutic resistance. We investigated the role of integrin-linked kinase (ILK) in regulating IL-6-driven Notch1 activation and the ability to target breast CSCs through ILK inhibition. Ectopic expression/short hairpin RNA-mediated knockdown of ILK, pharmacological inhibition of ILK with the small molecule T315, Western blot analysis, immunofluorescence, and luciferase reporter assays were used to evaluate the regulation of IL-6-driven Notch1 activation by ILK in IL-6-producing triple-negative breast cancer cell lines (MDA-MB-231, SUM-159) and in MCF-7 and MCF-7IL-6 cells. The effects of ILK on γ-secretase complex assembly and cellular localization were determined by immunofluorescence, Western blots of membrane fractions, and immunoprecipitation. In vivo effects of T315-induced ILK inhibition on CSCs in SUM-159 xenograft models were assessed by mammosphere assays, flow cytometry, and tumorigenicity assays. Results show that the genetic knockdown or pharmacological inhibition of ILK suppressed Notch1 activation and the abundance of the γ-secretase components presenilin-1, nicastrin, and presenilin enhancer 2 at the posttranscriptional level via inhibition of caveolin-1-dependent membrane assembly of the γ-secretase complex. Accordingly, knockdown of ILK inhibited breast CSC-like properties in vitro and the breast CSC subpopulation in vivo in xenograft tumor models. Based on these findings, we propose a novel function of ILK in regulating γ-secretase-mediated Notch1 activation, which suggests the targeting of ILK as a therapeutic approach to suppress IL-6-induced breast CSCs.

UR - http://www.scopus.com/inward/record.url?scp=84943155630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943155630&partnerID=8YFLogxK

U2 - 10.1016/j.neo.2015.06.001

DO - 10.1016/j.neo.2015.06.001

M3 - Article

VL - 17

SP - 497

EP - 508

JO - Neoplasia

JF - Neoplasia

SN - 1522-8002

IS - 6

ER -